| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Julian F Guest | Q59691971 |
| Miquel Serra | Q59691975 | ||
| Jaime Esteban | Q40283180 | ||
| P2093 | author name string | Giuliano Rizzardini | |
| Andrea Novelli | |||
| Anton G Manganelli | |||
| P2860 | cites work | Bayesian measures of model complexity and fit | Q56532420 |
| Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America | Q88172637 | ||
| Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis. | Q38514433 | ||
| A Systematic Literature Review of The Economic Implications of Acute Bacterial Skin And Skin Structure Infections (Absssis). | Q38624369 | ||
| Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift | Q39719043 | ||
| In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients | Q40252885 | ||
| Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target. | Q40988669 | ||
| In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program | Q41220588 | ||
| Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design | Q42544277 | ||
| Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial | Q42616087 | ||
| Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus | Q42652703 | ||
| National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections | Q43516352 | ||
| Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study | Q43694841 | ||
| Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections | Q43996924 | ||
| Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections | Q44732971 | ||
| Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective | Q46226517 | ||
| Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus | Q46429720 | ||
| A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria | Q46459065 | ||
| Linezolid for the treatment of infections caused by Gram-positive pathogens in China | Q46477911 | ||
| Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial | Q46649846 | ||
| Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections | Q46758156 | ||
| Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. | Q46894544 | ||
| Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. | Q46920279 | ||
| Utilization of the PICO framework to improve searching PubMed for clinical questions | Q21254606 | ||
| Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study | Q28384260 | ||
| Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan | Q33376899 | ||
| Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials | Q33378032 | ||
| Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis | Q33387451 | ||
| The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials. | Q33834856 | ||
| Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections | Q33836490 | ||
| Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam | Q34123811 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. | Q34390763 | ||
| Once-weekly dalbavancin versus daily conventional therapy for skin infection | Q34422888 | ||
| Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America | Q34425750 | ||
| A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection | Q34458664 | ||
| The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections | Q34618696 | ||
| Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials | Q34640925 | ||
| Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study | Q34900607 | ||
| Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin | Q35959558 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections | Q36927625 | ||
| Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature | Q36930855 | ||
| Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment | Q36991744 | ||
| New antibiotics for the management of complicated skin and soft tissue infections: are they any better? | Q37533556 | ||
| The tide of antimicrobial resistance and selection | Q37549390 | ||
| Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). | Q37628774 | ||
| Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials | Q37630016 | ||
| Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis | Q37637758 | ||
| Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections | Q37739469 | ||
| Complicated skin and soft tissue infection | Q37793714 | ||
| Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. | Q37888895 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| P304 | page(s) | e0187792 | |
| P577 | publication date | 2017-11-14 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis | |
| P478 | volume | 12 |
| Q57158658 | Antibiotic therapy for skin and soft tissue infections: a protocol for a systematic review and network meta-analysis | cites work | P2860 |
Search more.